Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting

BACKGROUND: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xuejiao, Liu, Yi, Sun, Jianai, Tong, Hongyan, Meng, Haitao, You, Liangshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657518/
https://www.ncbi.nlm.nih.gov/pubmed/38028949
http://dx.doi.org/10.1177/20406223231213251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657518/
https://www.ncbi.nlm.nih.gov/pubmed/38028949
http://dx.doi.org/10.1177/20406223231213251

Ejemplares similares